<DOC>
	<DOC>NCT02104154</DOC>
	<brief_summary>To establish the performance characteristics of the Samsung LABGEO PT10 by comparing the test results of the PT10 Hepatic assay with results obtained from an FDA-cleared chemistry analyzer.</brief_summary>
	<brief_title>Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting</brief_title>
	<detailed_description>To establish the correlation between measurand values as obtained from the Samsung LABGEO PT10 Hepatic Panel at the point of care, and the corresponding measurand values as obtained on a commercial clinical chemistry analyzer, with respect to prospectively collected human serum specimens.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Male or female subjects with a history of elevated liver enzymes or symptoms suggestive of elevated liver enzymes Presenting to the site and requiring testing for levels of liver enzymes as part of routine care at the site Subjects able and willing to provide written informed consent Subjects unable or unwilling to provide written informed consent Subjects with a lifethreatening disease or any serious, potentially lifethreatening medical illness that may compromise patient safety or study conduct</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>